Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (March 2018)
34 slides from Prescient Therapeutics's investor presentation, Mar 19, 2018
Slide 1: March 2018 Investor Presentation (ASX Release)
ASX Release March 2018 Investor Presentation Melbourne, Australia (19 March 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) provides a copy of the attached March 2018 Investor Presentation, ahead of final Phase 1b breast cancer results with PTX-200. For wo
Slide 2: About Prescient Therapeutics Limited
About Prescient Therapeutics Limited (Prescient) Prescient Therapeutics is a clinical stage oncology company developing targeted therapies that address specific mutations that drive cancer and contribute to resistance. Prescient’s lead drug candidate PTX-200 inhibits an important tumor survival path
Slide 3: Disclaimer and Safe Harbor
assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty t
Slide 4: Developing Novel Targeted Therapies to Beat Cancer
DEVELOPING NOVEL TARGETED THERAPIES TO BEAT CANCER ANTICIPATING PHASE 1B BREAST CANCER RESULTS Prescient Therapeutics Limited (ASX: PTX) Broker presentation March 2018
Slide 5: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on
Slide 6: Company Overview
COMPANY OVERVIEW 3 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 7: Investment Highlights
INVESTMENT HIGHLIGHTS 2 DRUGS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE • Multiple shots on goal with novel personalized cancer therapies • One of deepest clinical pipelines on the ASX • Funded through to value-accretive catalysts, with a fantastic share register • Great scientifi
Slide 8: Corporate Snapshot
CORPORATE SNAPSHOT KEY METRICS ASX Ticker PTX Market Capitalisation1 A$18.8 M (US$14.8 M) Total Issued Capital 211.3 M shares Cash Position2 A$6.0 M (US$4.7 M) Options 57.8 M Top 20 Own 52% Share Price1 A$0.089 (US$0.07) 6 month turnover1 22.7 M shares; A$1.6 M (US$1.3 M) SHARE PRICE PERFORMANCE SHA
Slide 9: Deep, Clinical Stage Product Pipeline
DEEP, CLINICAL STAGE PRODUCT PIPELINE • PTX-200 currently in three clinical trials • Advancing PTX-100 in rare hematological cancers - a transformative opportunity DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHASE 3 PTX-200 BREAST CANCER PTX-200 OVARIAN CANCER PTX-200 AML PTX-100 SOLID
Slide 10: Investment Decision Funnel for Any Biotech
INVESTMENT DECISION FUNNEL FOR ANY BIOTECH Is the drug in a clinical trial, or still pre-clinical? Both drugs clinical stage Is the trial conducted to US FDA standard? All INDs (under US FDA) Do the indications make clinical & Targeting unmet/poorly met medical commercial sense? needs – relaps
Slide 11: Drugs Don't Develop Themselves!
DRUGS DON’T DEVELOP THEMSELVES! PTX DEVELOPMENT TEAM WITH BENCH TO BEDSIDE SUCCESS Proven success from discovery and clinical development, through to FDA approvals • Professor and Chair, Department of Drug Discovery - Moffitt Cancer Center Said Sebti, PhD • Co-inventor of PTX-100 & PTX-200 Chief Sci
Slide 12: World Class Centers & Collaborations
WORLD CLASS CENTERS & COLLABORATIONS CONNECTICUT KANSAS NEW YORK FLORIDA PREVIOUS CLINICAL TRIALS CONDUCTED AT: 9 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 13: How Our Drugs Work: Molecular Switches
HOW OUR DRUGS WORK: “MOLECULAR SWITCHES” Akt & Ras are growth molecules found in cells – when they are stuck “on”, they send constant signals to the cancer cell to grow PTX’s drugs block the Akt & Ras growth pathways, PTX-100 switching the growth signals off and causing the cancer cell to die PTX-20
Slide 14: Turning Off Tumour Master Switches
TURNING OFF TUMOUR MASTER SWITCHES 11 ERSAHIN, T. ET AL; MOL. BIOSYST., 2015,11, 1946-1954
Slide 15: PTX-200
PTX-200 NOVEL AKT INHIBITION AML Breast cancer Ovarian cancer 12 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 16: Breast Cancer Overview
BREAST CANCER OVERVIEW • Breast cancer market currently US$10 B; due to double by 2023 • HER2- breast cancer has “flown under the radar” of drug developers, due to high profile successes in HER2+ drugs…but ~80% of breast cancers are still HER2- (TNBC & ER+) • Comparative lack of new drug development
Slide 17: High p-AKT Correlated With Poorer Breast Cancer Outcomes
HIGH P-AKT CORRELATED WITH POORER BREAST CANCER OUTCOMES • pAkt overexpression associated with higher risk of death and disease recurrence » Irrespective of population, status of hormone receptors, hormonal or trastuzumab treatment given • p-Akt overexpression is an adverse prognostic factor for bre
Slide 18: What Does Success Look Like for This Disease?
WHAT DOES SUCCESS LOOK LIKE FOR THIS DISEASE? • Complete eradication of disease= pathological complete response (pCR) • Partial eradication = partial response (PR). Complete + partial responses = overall response rate (ORR) • Studies on all sub-types of locally advanced breast cancer receiving weekl
Slide 19: Phase 1b Breast Cancer Trial Completed
PHASE 1B BREAST CANCER TRIAL COMPLETED • PTX-200 in combination with paclitaxel, followed by AC (doxorubicin & cyclophosphamide) • Patients with metastatic and locally advanced HER2- breast cancer » Represent s the majority of breast cancer patients » High p-Akt levels correlated with poorer outcome
Slide 20: Phase 1b AML Trial Underway
PHASE 1B AML TRIAL UNDERWAY • Phase 1 results with PTX-200 (monotherapy) very encouraging • Now PTX-200 + cytarabine in refractory or relapsed acute leukemia » 15 -18 patients » 3+3 design, single arm » Up to 4 dose levels of PTX-200 starting at 25 mg/m2 (days 1, 8, 15) » Cytarabine held constant at
Slide 21: Phase 1b Ovarian Cancer Trial
PHASE 1B OVARIAN CANCER TRIAL • Significant need for new products to treat platinum-resistant ovarian cancer • Testing PTX-200 plus carboplatin in patients with platinum resistant ovarian cancer • PTX-200 already proven overcome cisplatin resistance and synergize with cisplatin in pre-clinical studi
Slide 22: PTX-100
PTX-100 PHASE 1 IN SOLID TUMORS COMPLETED NOW PURSUING A TRANSFORMATIVE OPPORTUNITY IN RARE BLOOD CANCERS 19 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 23: Rare Diseases Can Transform Smaller Companies
RARE DISEASES CAN TRANSFORM SMALLER COMPANIES • Rare diseases (<200,000 patients in US) can present big opportunities for smaller companies • Markets may be too small for some Big Pharma, but are big enough to transform smaller companies • Attractions of rare diseases » Typically much smaller trials
Slide 24: Case Study: Folotyn
CASE STUDY : FOLOTYN • Developed by Allos, acquired by Spectrum Pharmaceuticals • For relapsed & refractory Peripheral T-cell lymphoma » 5,600 cases/year in US • Approved on overall response rate of 27% • Currently priced at US$450,540 per patient, per year 21 TARGETED THERAPIES YIELDING A DEEP CLIN
Slide 25: Ras Pathway, and RhoA in Particular
RAS PATHWAY, AND RHOA IN PARTICULAR, ARE IMPLICATED IN A NUMBER OF HEMATOLOGICAL MALIGNANCIES Frequency of RhoA mutations in human malignancies Indications of interest for PTX-100 • In addition, N-Ras and K-Ras contribute to several heme malignancies including: » Acute Myeloid Leukemia (AML) » Chron
Slide 26: PTX-100 the Most Advanced Drug Targeting RhoA
PTX-100 THE MOST ADVANCED DRUG TARGETING RHOA PTX-100 • Only 12 RhoA inhibitors in development in 1 oncology » No others are in the clinic NO. OF DRUGS IN DEVELOPMENT » None are in hematology indications » PTX-100 is the most advanced, with Phase 1 7 trial in solid tumours completed ADDRESSING RHOA
Slide 27: Value Proposition
VALUE PROPOSITION 24 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 28: Significant Valuation Arbitrage
SIGNIFICANT VALUATION ARBITRAGE Robust science and solid progress, …But when the science is robust, but still currently offering incredible value… the valuation gap will not last forever! 500 450 400 350 300 ASX peer average 250 A$228M 200 150 100 50 - PTX IMM PXS NEU BNO OPT SPL VLA 25 GOOGLE FINAN
Slide 29: Targeted Therapies Case Study #1: Loxo
TARGETED THERAPIES CASE STUDY #1: LOXO Bayer agrees cancer drug deal with Loxo worth up to $1.55 bln November 14, 2017, 10:08:00 AM EDT By Reuters • Loxo Oncology (NASDAQ: LOXO); US$3.4B market cap • TRK inhibitor targeting cancers with TRK fusions • Deal for LOXO-101 and LOXO-195 • In mid-stage cli
Slide 30: Targeted Therapies Case Study #2: Blueprint
TARGETED THERAPIES CASE STUDY #2: BLUEPRINT • Blueprint Medicines (NASDAQ: BPMC) • Target therapies for cancer based on genomically defined diseases (abnormal kinase activation) • 4x Phase 1 drugs • 3 x discovery programs • IPO April 2015: Valuation: US$398M; $16/share • Today: Valuation: US$3.8 B;
Slide 31: Prescient Following the Same Development Path
PRESCIENT FOLLOWING THE SAME DEVELOPMENT PATH • Prescient Therapeutics (ASX: PTX); market cap $18M • Target therapies for cancer • Hyper pAkt – PTX-200 » Orphan drug designation in AML • Ras pathway mutations – PTX-100 » Ultra-orphan RhoA mutant lymphomas • A step behind some US peers, but treading
Slide 32: In the Next Months We Will Work Towards
IN THE NEXT 12 MONTHS WE WILL WORK TOWARDS: • Removal of clinical hold on PTX-200 breast cancer trial (already done) • Final data on the Phase 1b PTX-200 breast cancer trial • Manufacturing run of PTX-100 and additional inventory of PTX-200 • Pre-clinical work in PTX-100 in RhoA mutant cancers • Com
Slide 33: Investment Highlights
INVESTMENT HIGHLIGHTS 2 DRUGS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE • Multiple shots on goal with novel personalized cancer therapies • One of deepest clinical pipelines on the ASX • Funded through to value-accretive catalysts, with a fantastic share register • Great scientifi
Slide 34: Contact
CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com 31 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Prescient Therapeutics — Investor Presentation (March 2018) on 6ix